Nasdaq:BCYC
BICYCLE THERAPEUTICS PLC
A clinical-stage biotech firm advancing proprietary therapies for oncology and fibrosis with significant cash reserves but no commercial revenue yet.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock due to the company's massive cash hoard of nearly $900M, which offers a long runway to navigate clinical trials and potential commercialization. The innovative cell-free platform technology presents a high-risk, high-reward opportunity if any asset achieves regulatory approval in lucrative oncology markets.
Bear Case
The stock carries extreme risk given the company has generated no profit for five consecutive years with a cumulative retained earnings deficit exceeding $680M. Investors face the prospect of total capital erosion if clinical trials fail or if the company cannot secure new financing before burning through its cash reserves.
About BICYCLE THERAPEUTICS PLC
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancer and fibrotic diseases. The company primarily operates in the United States and Europe, leveraging its proprietary platform to advance targeted treatments through strategic partnerships and internal research.
Analysis
Management Discussion
The company reported $35.3M in revenue for 2024, driven by strategic collaborations, while continuing to incur a significant net loss of $169.0M due to heavy investment in research and development totaling $173.0M. Despite the operating cash flow burn of $164.7M, the firm successfully maintained its liquidity with ending cash at $880.1M, aided by substantial financing inflows.
Industry Overview
The biotechnology sector is characterized by long development cycles, high regulatory hurdles, and significant upfront investment required to bring new therapies to market. Companies in this space often operate at a loss while building intellectual property portfolios that can generate value only upon successful product launches.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $14.5M | $27.0M | $35.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $14.5M | $27.0M | $35.3M |
| Operating Expenses | $131.1M | $216.9M | $245.1M |
| Operating Income | $-116.7M | $-189.9M | $-209.9M |
| R&D | $81.6M | $156.5M | $173.0M |
| G&A | $49.5M | $60.4M | $72.2M |
| Stock-Based Comp | $26.8M | $32.5M | $38.1M |
| D&A | $3.7M | $6.5M | $7.2M |
| Depreciation | $3.7M | $6.5M | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $2.4M | $10.7M | $36.1M |
| Interest Expense | $3.3M | $3.3M | — |
| Pre-Tax Income | $-114.2M | $-179.2M | $-173.8M |
| Income Tax | $-1.5M | $1.5M | $-4.8M |
| Continuing Ops | $-112.7M | $-180.7M | $-169.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-112.7M | $-180.7M | $-169.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-112.7M | $-180.7M | $-169.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $369.4M | $561.9M | $928.6M |
| Cash & Equivalents | $339.2M | $526.4M | $879.5M |
| Accounts Receivable | $2.0M | $0 | $0 |
| Prepaid Expenses | $9.0M | $11.4M | $13.4M |
| Other Current Assets | $19.2M | $24.0M | $35.7M |
| Long-Term Assets | $41.2M | $33.5M | $28.3M |
| PP&E (Net) | $19.1M | $14.5M | $9.5M |
| Operating Leases | $13.7M | $13.2M | $7.7M |
| Other LT Assets | $8.5M | $5.8M | $11.1M |
| Total Assets | $410.6M | $595.3M | $956.9M |
| Current Liabilities | $53.3M | $69.5M | $67.2M |
| Accounts Payable | $6.5M | $13.1M | $15.8M |
| Current Leases | $3.1M | $4.9M | $5.3M |
| Other Current Liab | $17.3M | $20.1M | $4.9M |
| Long-Term Liabilities | $86.5M | $154.9M | $96.6M |
| Long-Term Debt | $30.3M | $30.7M | — |
| LT Operating Leases | $10.9M | $9.4M | $4.0M |
| Other LT Liab | $45.3M | $114.8M | $92.6M |
| Total Liabilities | $139.8M | $224.4M | $163.8M |
| Shareholders' Equity | $270.8M | $370.9M | $793.1M |
| Paid-In Capital | $601.1M | $883.4M | $1.47B |
| Retained Earnings | $-331.1M | $-511.8M | $-680.8M |
| AOCI | $387.0K | $-1.3M | $119.0K |
| Total L&E | $410.6M | $595.3M | $956.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-112.7M | $-180.7M | $-169.0M |
| Non-Cash Adjustments | $11.6M | $42.3M | $26.1M |
| Working Capital Changes | $15.0M | $77.7M | $-21.8M |
| Cash from Operations | $-86.1M | $-60.6M | $-164.7M |
| Capital Expenditures | $19.0M | $2.9M | $1.2M |
| Cash from Investing | $-19.0M | $-2.9M | $-1.2M |
| Debt Repayments | — | — | $31.9M |
| Cash from Financing | $6.7M | $250.0M | $519.8M |
| FX Effect | $-1.1M | $1.3M | $-694.0K |
| Net Change in Cash | $-99.5M | $187.8M | $353.1M |
| Beginning Cash | $438.7M | $339.2M | $527.0M |
| Ending Cash | $339.2M | $527.0M | $880.1M |
Frequently Asked Questions
How does BICYCLE THERAPEUTICS PLC make money?
The company's operations are concentrated in early-stage drug development, specifically targeting cancer indications and fibrotic diseases such as systemic sclerosis. Revenue is currently derived from upfront payments and milestones associated with its licensing agreements rather than product sales.
What are the main risks for BCYC?
As a clinical-stage company with no commercial products on the market, the firm faces total reliance on successful drug development outcomes to generate future revenue. The absence of accounts receivable highlights a lack of current sales, creating cash flow volatility dependent on partnership milestones. High operating expenses driven by R&D and administrative costs continue to widen the net loss position.
What is BCYC's competitive advantage?
Bicycle Therapeutics possesses a unique cell-free synthetic biology platform that enables the engineering of novel therapeutic proteins without viral vectors. The company benefits from a robust balance sheet with over $879M in cash, providing substantial runway for R&D and commercialization efforts without immediate dilution pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.